<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）于周三公布了其季度财报。公司报告本季度每股收益（EPS）为（$0.22），超出市场共识预期的（$0.30）$0.08，FiscalAI 报道。Recursion Pharmaceuticals 的净利润率为负 863.37%，股本回报率为负 63.98%。该公司本季度的收入为 647 万美元，而分析师预期为 1578 万美元。在去年同期，公司每股收益为（$0.50）。公司的收入同比下降了 56.8%。</p>
<ul>
<li>2 个理由说明 Absci 可能是 AI 生物技术的未来，以及 1 个风险</li>
</ul>
<p>以下是 Recursion Pharmaceuticals 电话会议的关键要点：</p>
<ul>
<li><strong>REC-4881：</strong> 公司报告的 FAP 临床概念验证显示，前癌性息肉显著减少，且反应持久，正在与 FDA 进行持续沟通以定义潜在的注册路径。</li>
<li><strong>REC-1245（RBM39 降解剂）：</strong> 来自 16 名患者的早期 DAHLIA I 期数据报告没有剂量限制毒性，PD 确认的靶点参与和 PK 支持每日给药，预计在下半年将有更多剂量递增和更全面的 PK/PD 结果。</li>
<li><strong>REC-4539（LSD1 抑制剂）：</strong> 第一名患者在 I 期中接受了该分子的给药，旨在降低血小板减少症风险，并且能够穿透大脑；初步的 PK 和安全性数据预计在 2027 年下半年发布。</li>
<li>平台和模型的进展（TxPert，TxFM）以及公司报告的效率声明——例如，超过 50PB 的多模态数据，合成化合物减少约 90%，开发候选药物的进展速度约为 2 倍——正在被应用，但仍需通过未来的结果进行独立验证。</li>
<li>财务状况：现金 665 百万美元，预计资金可持续到 2028 年初，运营费用同比减少 30%，2026 年现金运营费用指导低于 390 百万美元，管理层表示这将支持近期里程碑而无需额外融资。</li>
</ul>
<h2>Recursion Pharmaceuticals 股票上涨 1.3%</h2>
<p>纳斯达克 RXRX 周三上涨 0.05 美元，达到 3.42 美元。该公司交易了 14,705,881 股，较其平均交易量 16,692,518 股有所减少。公司的市值为 18 亿美元，市盈率为-2.31，贝塔系数为 1.05。Recursion Pharmaceuticals 的 12 个月低点为 2.80 美元，12 个月高点为 7.18 美元。该股票的 50 日移动平均为 3.40 美元，200 日移动平均为 4.16 美元。公司的流动比率为 5.50，速动比率为 5.50，债务与股本比率为 0.01。</p>
<h2>分析师评级上调与下调</h2>
<ul>
<li>这些是 NVIDIA 13F 投资组合中唯一的 6 只股票</li>
</ul>
<p>多家研究公司最近对 RXRX 发表了评论。华尔街 Zen 在 3 月 28 日的研究报告中将 Recursion Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Needham &amp; Company LLC 在 2 月 26 日的研究报告中重申了 “买入” 评级，并对 Recursion Pharmaceuticals 的股票设定了 8.00 美元的目标价。Weiss Ratings 在 4 月 21 日的研究报告中重申了 Recursion Pharmaceuticals 的 “卖出（d-）” 评级。摩根大通在 4 月 30 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 11.00 美元下调至 10.00 美元，并对该股票设定了 “增持” 评级。最后，美国银行在 2 月 25 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并对该股票设定了 “中性” 评级。两位股票研究分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat，Recursion Pharmaceuticals 目前的共识评级为 “持有”，共识目标价为 9.20 美元。</p>
<p><strong>获取我们关于 Recursion Pharmaceuticals 的最新报告</strong></p>
<h2>内部人员买卖</h2>
<ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 最爱吗？</li>
</ul>
<p>在相关消息中，董事 Blake Borgeson 于 4 月 7 日星期二出售了 30,000 股该股票，交易价格为每股 3.10 美元，总交易额为 93,000.00 美元。交易后，该董事直接持有公司股票 6,229,863 股，价值 19,312,575.30 美元。这代表其持股比例减少了 0.48%。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席财务官 Ben R. Taylor 于 2 月 18 日星期三出售了 13,426 股该股票，交易价格为每股 3.08 美元，总交易额为 41,352.08 美元。交易后，首席财务官直接持有公司 1,195,349 股，价值约 3,681,674.92 美元。这代表其持股比例减少了 1.11%。该交易的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人员共出售了 79,680 股公司股票，价值 256,121 美元。8.43% 的股票由公司内部人员持有。</p>
<h2>机构资金流入与流出</h2>
<p>几家机构投资者最近买卖了 RXRX 的股票。State Street Corp 在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 38.7%。State Street Corp 目前拥有 25,333,888 股该公司的股票，价值 103,616,000 美元，此前在上个季度又购买了 7,064,963 股。ARK Investment Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 11.2%。ARK Investment Management LLC 目前拥有 37,316,856 股该公司的股票，价值 152,626,000 美元，此前在此期间又购买了 3,771,357 股。Millennium Management LLC 在第四季度购买了 Recursion Pharmaceuticals 的新头寸，价值约 6,118,000 美元。Geode Capital Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 13.6%。Geode Capital Management LLC 目前拥有 10,934,252 股该公司的股票，价值 44,731,000 美元，此前在此期间又购买了 1,310,695 股。最后，Two Sigma Investments LP 在第三季度将其在 Recursion Pharmaceuticals 的持股增加了 109.9%。Two Sigma Investments LP 目前拥有 2,450,805 股该公司的股票，价值 11,960,000 美元，此前在此期间又收购了 1,282,992 股。机构投资者和对冲基金持有该公司 89.06% 的股票。</p>
<h2>Recursion Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Recursion Pharmaceuticals, Inc NASDAQ: RXRX 是一家生物制药公司，结合了先进的自动化、人工智能和高通量生物学，以发现和开发新型治疗药物。该公司的专有平台将深度学习算法与大规模细胞成像和化学生物学相结合，使得能够快速识别各种适应症的潜在药物候选者。通过自动化复杂的实验室工作流程并利用计算模型，Recursion 旨在加速药物发现过程并扩大可以解决的靶点范围。</p>
<p>Recursion 提供的核心是其数字生物学平台，该平台在不同的化学和遗传干扰下捕获数十亿个细胞图像。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们认为比 Recursion Pharmaceuticals 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhSWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
<p>在你考虑 Recursion Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Recursion Pharmaceuticals 并不在名单上。</p>
<p>虽然 Recursion Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RXRX

标普全球医疗股指数 ETF - iShares

动态生物技术与基因组 ETF - Invesco

<p>Recursion Pharmaceuticals（纳斯达克代码：RXRX）报告的季度每股收益为（$0.22），超出预期的（$0.30）$0.08。该公司的收入为 647 万美元，显著低于预期的 1578 万美元，同比下降 56.8%。尽管净利润率为负 863.37%，股本回报率为负 63.98%，但该公司仍保持强劲的现金储备，达到 6.65 亿美元，预计可支持运营至 2028 年初。股价上涨 1.3%，至 3.42 美元，分析师评级不一，市场共识目标价为 9.20 美元</p>

<p>Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08, FiscalAI reports. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on equity of 63.98%. The firm had revenue of $6.47 million during the quarter, compared to analysts' expectations of $15.78 million. During the same period in the prior year, the company posted ($0.50) EPS. The company's revenue was down 56.8% on a year-over-year basis.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals（纳斯达克代码：RXRX - 获取免费报告）于周三公布了其季度财报。公司报告本季度每股收益（EPS）为（$0.22），超出市场共识预期的（$0.30）$0.08，FiscalAI 报道。Recursion Pharmaceuticals 的净利润率为负 863.37%，股本回报率为负 63.98%。该公司本季度的收入为 647 万美元，而分析师预期为 1578 万美元。在去年同期，公司每股收益为（$0.50）。公司的收入同比下降了 56.8%。</p>
</div><ul>
<li>2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>2 个理由说明 Absci 可能是 AI 生物技术的未来，以及 1 个风险</li>
</ul>
</div><p>Here are the key takeaways from Recursion Pharmaceuticals' conference call:</p>
<div class="lb-trans"><p>以下是 Recursion Pharmaceuticals 电话会议的关键要点：</p>
</div><ul>
<li><strong>REC-4881:</strong> Company-reported clinical proof-of-concept in FAP showing significant reductions in precancerous polyps with durable responses, and ongoing FDA engagement to define a potential registrational path.</li>
<li><strong>REC-1245 (RBM39 degrader):</strong> Early DAHLIA Phase I data from 16 patients report no dose-limiting toxicities, PD-confirmed target engagement and PK supportive of daily dosing, with more dose-escalation and fuller PK/PD readouts expected in H2.</li>
<li><strong>REC-4539 (LSD1 inhibitor):</strong> First patient dosed in Phase I for a molecule designed to reduce thrombocytopenia risk and that is brain-penetrant; initial PK and safety data are expected in H2 2027.</li>
<li>Platform and model advances (TxPert, TxFM) and company-reported efficiency claims — e.g., &gt;50 PB of multimodal data, ~90% fewer compounds synthesized and ~2x faster progress to development candidates — are being deployed but remain company-reported metrics to be independently validated by future outcomes.</li>
<li>Financial position: $665M in cash, asserted runway into early 2028, a 30% year-over-year reduction in operating expenses, and 2026 cash OpEx guidance under $390M, which management says funds near-term milestones without additional financing.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>REC-4881：</strong> 公司报告的 FAP 临床概念验证显示，前癌性息肉显著减少，且反应持久，正在与 FDA 进行持续沟通以定义潜在的注册路径。</li>
<li><strong>REC-1245（RBM39 降解剂）：</strong> 来自 16 名患者的早期 DAHLIA I 期数据报告没有剂量限制毒性，PD 确认的靶点参与和 PK 支持每日给药，预计在下半年将有更多剂量递增和更全面的 PK/PD 结果。</li>
<li><strong>REC-4539（LSD1 抑制剂）：</strong> 第一名患者在 I 期中接受了该分子的给药，旨在降低血小板减少症风险，并且能够穿透大脑；初步的 PK 和安全性数据预计在 2027 年下半年发布。</li>
<li>平台和模型的进展（TxPert，TxFM）以及公司报告的效率声明——例如，超过 50PB 的多模态数据，合成化合物减少约 90%，开发候选药物的进展速度约为 2 倍——正在被应用，但仍需通过未来的结果进行独立验证。</li>
<li>财务状况：现金 665 百万美元，预计资金可持续到 2028 年初，运营费用同比减少 30%，2026 年现金运营费用指导低于 390 百万美元，管理层表示这将支持近期里程碑而无需额外融资。</li>
</ul>
</div><h2>Recursion Pharmaceuticals Stock Up 1.3%</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 股票上涨 1.3%</h2>
</div><p>NASDAQ RXRX traded up $0.05 on Wednesday, hitting $3.42. 14,705,881 shares of the company were exchanged, compared to its average volume of 16,692,518. The company has a market cap of $1.80 billion, a PE ratio of -2.31 and a beta of 1.05. Recursion Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $7.18. The stock has a fifty day moving average of $3.40 and a 200-day moving average of $4.16. The company has a current ratio of 5.50, a quick ratio of 5.50 and a debt-to-equity ratio of 0.01.</p>
<div class="lb-trans"><p>纳斯达克 RXRX 周三上涨 0.05 美元，达到 3.42 美元。该公司交易了 14,705,881 股，较其平均交易量 16,692,518 股有所减少。公司的市值为 18 亿美元，市盈率为-2.31，贝塔系数为 1.05。Recursion Pharmaceuticals 的 12 个月低点为 2.80 美元，12 个月高点为 7.18 美元。该股票的 50 日移动平均为 3.40 美元，200 日移动平均为 4.16 美元。公司的流动比率为 5.50，速动比率为 5.50，债务与股本比率为 0.01。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><ul>
<li>These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>这些是 NVIDIA 13F 投资组合中唯一的 6 只股票</li>
</ul>
</div><p>A number of research firms have recently commented on RXRX. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, March 28th. Needham &amp; Company LLC reaffirmed a &#34;buy&#34; rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 21st. JPMorgan Chase &amp; Co. reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday, April 30th. Finally, Bank of America reduced their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a &#34;neutral&#34; rating on the stock in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Recursion Pharmaceuticals currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $9.20.</p>
<div class="lb-trans"><p>多家研究公司最近对 RXRX 发表了评论。华尔街 Zen 在 3 月 28 日的研究报告中将 Recursion Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。Needham &amp; Company LLC 在 2 月 26 日的研究报告中重申了 “买入” 评级，并对 Recursion Pharmaceuticals 的股票设定了 8.00 美元的目标价。Weiss Ratings 在 4 月 21 日的研究报告中重申了 Recursion Pharmaceuticals 的 “卖出（d-）” 评级。摩根大通在 4 月 30 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 11.00 美元下调至 10.00 美元，并对该股票设定了 “增持” 评级。最后，美国银行在 2 月 25 日的研究报告中将 Recursion Pharmaceuticals 的目标价从 7.00 美元下调至 6.00 美元，并对该股票设定了 “中性” 评级。两位股票研究分析师对该股票给予了 “买入” 评级，两位给予了 “持有” 评级，一位给予了 “卖出” 评级。根据 MarketBeat，Recursion Pharmaceuticals 目前的共识评级为 “持有”，共识目标价为 9.20 美元。</p>
</div><p><strong>Get Our Latest Report on Recursion Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Recursion Pharmaceuticals 的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员买卖</h2>
</div><ul>
<li>Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?</li>
</ul>
<div class="lb-trans"><ul>
<li>突然上升：Recursion Pharmaceuticals 是 NVIDIA 的 AI 最爱吗？</li>
</ul>
</div><p>In related news, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $3.10, for a total transaction of $93,000.00. Following the transaction, the director directly owned 6,229,863 shares of the company's stock, valued at $19,312,575.30. This represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ben R. Taylor sold 13,426 shares of the stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total transaction of $41,352.08. Following the transaction, the chief financial officer directly owned 1,195,349 shares in the company, valued at approximately $3,681,674.92. This represents a 1.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 79,680 shares of company stock valued at $256,121 over the last ninety days. 8.43% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Blake Borgeson 于 4 月 7 日星期二出售了 30,000 股该股票，交易价格为每股 3.10 美元，总交易额为 93,000.00 美元。交易后，该董事直接持有公司股票 6,229,863 股，价值 19,312,575.30 美元。这代表其持股比例减少了 0.48%。该交易已在证券交易委员会的法律文件中披露，可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，首席财务官 Ben R. Taylor 于 2 月 18 日星期三出售了 13,426 股该股票，交易价格为每股 3.08 美元，总交易额为 41,352.08 美元。交易后，首席财务官直接持有公司 1,195,349 股，价值约 3,681,674.92 美元。这代表其持股比例减少了 1.11%。该交易的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人员共出售了 79,680 股公司股票，价值 256,121 美元。8.43% 的股票由公司内部人员持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入与流出</h2>
</div><p>Several institutional investors have recently bought and sold shares of RXRX. State Street Corp raised its holdings in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company's stock valued at $103,616,000 after purchasing an additional 7,064,963 shares during the last quarter. ARK Investment Management LLC boosted its position in Recursion Pharmaceuticals by 11.2% during the fourth quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company's stock worth $152,626,000 after purchasing an additional 3,771,357 shares during the period. Millennium Management LLC bought a new position in Recursion Pharmaceuticals during the fourth quarter worth about $6,118,000. Geode Capital Management LLC boosted its position in Recursion Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 10,934,252 shares of the company's stock worth $44,731,000 after purchasing an additional 1,310,695 shares during the period. Finally, Two Sigma Investments LP boosted its position in shares of Recursion Pharmaceuticals by 109.9% in the third quarter. Two Sigma Investments LP now owns 2,450,805 shares of the company's stock valued at $11,960,000 after acquiring an additional 1,282,992 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近买卖了 RXRX 的股票。State Street Corp 在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 38.7%。State Street Corp 目前拥有 25,333,888 股该公司的股票，价值 103,616,000 美元，此前在上个季度又购买了 7,064,963 股。ARK Investment Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 11.2%。ARK Investment Management LLC 目前拥有 37,316,856 股该公司的股票，价值 152,626,000 美元，此前在此期间又购买了 3,771,357 股。Millennium Management LLC 在第四季度购买了 Recursion Pharmaceuticals 的新头寸，价值约 6,118,000 美元。Geode Capital Management LLC 在第四季度将其在 Recursion Pharmaceuticals 的持股增加了 13.6%。Geode Capital Management LLC 目前拥有 10,934,252 股该公司的股票，价值 44,731,000 美元，此前在此期间又购买了 1,310,695 股。最后，Two Sigma Investments LP 在第三季度将其在 Recursion Pharmaceuticals 的持股增加了 109.9%。Two Sigma Investments LP 目前拥有 2,450,805 股该公司的股票，价值 11,960,000 美元，此前在此期间又收购了 1,282,992 股。机构投资者和对冲基金持有该公司 89.06% 的股票。</p>
</div><h2>Recursion Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Recursion Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Recursion Pharmaceuticals, Inc NASDAQ: RXRX is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.</p>
<div class="lb-trans"><p>Recursion Pharmaceuticals, Inc NASDAQ: RXRX 是一家生物制药公司，结合了先进的自动化、人工智能和高通量生物学，以发现和开发新型治疗药物。该公司的专有平台将深度学习算法与大规模细胞成像和化学生物学相结合，使得能够快速识别各种适应症的潜在药物候选者。通过自动化复杂的实验室工作流程并利用计算模型，Recursion 旨在加速药物发现过程并扩大可以解决的靶点范围。</p>
</div><p>At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.</p>
<div class="lb-trans"><p>Recursion 提供的核心是其数字生物学平台，该平台在不同的化学和遗传干扰下捕获数十亿个细胞图像。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Recursion Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Recursion Pharmaceuticals 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UlhSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RXRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Recursion Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Recursion Pharmaceuticals 吗？</h2>
</div><p>Before you consider Recursion Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Recursion Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Recursion Pharmaceuticals 并不在名单上。</p>
</div><p>While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Recursion Pharmaceuticals 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Recursion Pharmaceuticals (NASDAQ:RXRX) 公布季度财务业绩